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Abstract
The present review summarizes the literature-acquired knowledge as well as author’s
own experience in conducting aero-allergen immunotherapy, particularly in subcutane-
ous route of administration (SCIT) of all modalities of respiratory allergy disease from
allergic rhinosinusitis, bronchial asthma to united airway disease. Because of the better
adherence resulting in appropriate efficacy in connection with satisfactory safety, the
author favours conventional schedules of subcutaneous route of therapeutic interven-
tion. Given the lack of specific biomarker in monitoring treatment course, the main control
mechanism of efficacy is the evaluation of quality of life using simple evaluation scale as
visual analogue scale or standardized respiratory allergy questionnaires. The future of
allergen immunotherapy should be focused on new routes of allergen administration
(e.g. oral, epicutaneous, intradermal, intralymphatic) and on the searching potential
biomarkers which could be objectively measured and easily accessible from body fluids
(blood, nasal secretion, sputum). The combination of estimated biomarkers obtained
from biological samples in conjunction with evaluation of quality of life could lead to the
generation of the overall satisfactory monitoring protocol.
Keywords: allergen immunotherapy, routes of administration, adjuvants, compliance,
future treatment
1. Introduction
Allergic diseases are considered as major global public health issue. Among them, respiratory
allergies represent 1 of 10 most common diseases of affluence. At present, IgE sensitization
to foreign proteins in the environment is rising up to 40% of the worldwide population,
especially in highly industrialized countries [1].  Only in the United States, prevalence of
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asthma reported in 2014 was 8.6% (6.3 million) and 7.4% (17.7 million) among children and
adults, respectively. Mortality on asthma in 2013 reaches 1.1 deaths per 100,000 of the United
States  population [2,  3].  At  least  similar  percentage rate  could be reported in European
countries also. Approximately, one-fifth of the world population suffers from upper respira-
tory allergies (hay fever, allergic rhinosinusitis).
Prevalence of asthma is still rising in many high as well as low income countries, likewise
impact of allergic diseases continue to grow. According to the World Health Organization
(WHO), the number of patients having asthma is 300 million, and with the rising trends, it is
expected to increase to 400 million, by 2025. Even though in majority of cases respiratory
allergies are not life-threatening diseases, it is necessary to say that patients with asthma and/
or other respiratory allergies have reduced quality of life [4] which is comparable to moderate
chronic coronary ischemia.
Asthma and allergic rhinosinusitis are linked by epidemiological, physiological, and patho-
logical characteristics. The genetic predisposition to develop IgE-mediated sensitivity to
common aero-allergens is the strongest predicting factor for the development of both diseases
[5]. Facts are supported by the concept of unifying the management of these disorders. The
united airway disease (UAD) hypothesis proposes that upper and lower airway disease, both
are manifestations of a single inflammatory process within the respiratory tract.
First-line treatment includes avoidance and minimization of exposure when possible. Medi-
cation, including antihistamines, bronchodilators, leukotriene inhibitors, and steroids, may be
used to reverse some of the symptoms of allergic reactions. Pharmacotherapy alone has no
effect on the progression of the disease and treatment has to be administered repeatedly as
long as symptoms prevail, which often means life-long [6]. It can be postulated that allergen
avoidance and pharmacotherapy alone cannot control the disease. Only allergen immuno-
therapy has the disease-modifying potential and should be included in the algorithm of
optimal therapeutic strategy.
Allergen immunotherapy is a form of parenteral (subcutaneous) or oral (sublingual) medica-
tion, designed to prevent or lessen an allergic reaction. Its mechanism of action is based upon
the body’s production of different antibodies to an antigen depending on how the antigen is
introduced into the body. Allergy immunotherapy induces immunological tolerance and
changes the course of disease. It is typically used in individuals after a trial of conservative
treatment, when avoidance and medications has been found to be inadequate.
In 2000, American College of Allergy, Asthma and Immunology (ACAAI) organized an
international conference “Immunotherapy in Allergic Asthma” where key board of the
meeting summarized that allergen immunotherapy is an effective treatment for allergic asthma
and also it prevents the early onset of asthma in children with allergic rhinitis. These conclu-
sions were subsequently confirmed by The Preventive Allergy Treatment (PAT) study pub-
lished in February 2002 [7]. The study concluded that pollen immunotherapy significantly
reduces the development of asthma in children with seasonal allergic rhinoconjunctivitis, and
also methacholine-induced bronchial hyper responsiveness was improved. Allergen immu-
notherapy can also prevent the development of sensitization to new allergens [8]. Active
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therapy resulted in a statistically significant reduction in rhinitis, conjunctivitis, and bronchial
reactivity, showed a reduction in the need for medication, a reduction in bronchial hyperres-
ponsiveness, and improvement in forced expiratory volume in 1 s (FEV1) [9].
Allergen immunotherapy does not cure allergies; immunotherapy aims to make a person less
sensitive to allergens. In some cases, allergic symptoms may be controlled to the point of
disappearance, allowing a person to avoid allergen reactions. Both forms of allergen immu-
notherapy (subcutaneous, sublingual) are used for the management of allergic rhinitis, allergic
conjunctivitis, and allergic asthma, however, subcutaneous administration route is used for
hymenoptera sensitivity only [10].
2. History of allergen immunotherapy
The first known historical remark about perception of immunity is dated to 430 B.C. when
Thucydides recorded “recovery from plague-endowed protection from repeated attacks” [11].
Other pre-Christian reference by Plinius described the “principle” of allergen-specific immu-
notherapy when King Mithridates VI from Pontos (132–163 B.C.) tried to protect himself
against poisoning. He had used increased doses of snake venom to make himself immune
against the toxin. Plinius did not report the result of such procedure [12].
The real development in immunological treatment started approximately at the end of
nineteenth and at the beginning of the twentieth century, but research was mostly orientated
on how to protect humans against infective diseases. Parallel with these trends, scientists as
Besredka, Pirquet, Dunbar, Holbrock-Curtis experimented with induction of “tolerance” by
administration of various sera (hyper immune animal sera, mixtures of various pollens) in
animal experiments as well as on treatment of human beings. However, due to significant side-
effects of treatment (including one report of death), procedures were discontinued [12].
In the year 2011, worldwide allergy-immunology community celebrated 100 years of allergen
immunotherapy, since the first successful use of this form of treatment by Leonard Noon (1878–
1913) at St. Mary’s Hospital in London in 1911. It is interesting to say that in 1928 in the same
hospital one floor above Alexander Fleming discovered penicillin, the first antibiotic which
has broad consequences for mankind.
Noon and Cantab published, in 10 June 1911 in Lancet [13], successful desensitization with
pollen extract (Phleum pratense). In this first use of parental immunotherapy, they administered
very low, increasing doses of the pollen extract by intradermal injections at intervals of 3–4
days. Following this therapy, the researchers demonstrated an improvement in hay fever
symptoms. They monitored the reactivity of their hay fever patient with conjunctival provo-
cation tests and observed that a single drop of highly diluted grass pollen extract prepared
according to Dunbar’s method was still sufficient to trigger a conjunctival reaction in sensitive
patients. Noon left his work for following hay fever seasons in hands of his colleague and close
friend John Freeman, while he knew his advanced tuberculosis would keep him from finishing
his work. In February 1913, only 2 years after the discovery, Leonard Noon died from florid
pulmonary tuberculosis at the age of only 35 [14].
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Noon’s immune-pathologic interpretation of possible mechanisms which was strongly
influenced by Dunbar’s thought was incorrect in claiming that the disease is caused by the
exposure to a toxin, present in pollen, which could even induce antitoxin when injected into
rabbits or horses. Administering little quantities of pollen extract to patients would actively
immunize them [15].
John Freeman (1877–1962) continued in pending work and he had published early results in
the same year 1911 [16]. After 3 years of treatment in 1914 (1 year after Noon’s death), he
summarized their results in the paper “Vaccination against hay fever: report of results during
the last three years” in the same medical journal [17].
On the opposite coast of the Atlantic Ocean, the pioneer publication concerning the allergen
immunotherapy appeared in 1913. George Cloves reported on the treatment of autumnal hay
fever by vaccination with aqueous extract of the pollen of ragweed. He concluded all eight
treated cases experienced improvement of general symptoms [18]. In 1915, Robert Cooke, the
founding director of one of the first allergy clinics in the United States: “The Institute of Allergy
Roosevelt Hospital, New York” published his own experience in Laryngoscope “The treatment
of hay fever by active immunization” [19].
In years 1918–1922, Robert Cooke introduced a suggested mechanism of action for allergen
injections as a “desensitization or hyposensitization,” analogous to tolerance achieved in
experimental anaphylaxis induced in animals. This concept suggested that the injections of an
increasing amount of allergen or antigen slowly neutralized those antibodies responsible for
the allergic reaction [11]. Cooke together with Mary Loveless have introduced the concept of
specific blocking antibody: “the development under treatment of a peculiar blocking or
inhibiting type of immune body that prevents the action of allergen on the sensitizing anti-
body” [20]. Twenty years later, Cooke confirmed his assumption that “serum factor” for
inhibition was most likely gamma globulin (IgG) in electrophoretic mobility studies in
ragweed-treated patients [21].
Next 30 years were strongly influenced by notable socio-economic disturbances as WWI, Wall
Street Crash, Great Depression, and WWII. One remarkable publication from that period
(1937), which has to be mentioned, was the report about depot allergenic vaccines for delayed
absorption: alum adsorption [22]. Aluminum adjuvants function as delivery systems by
generating depots that trap antigens/allergen at the injection site, providing slow release in
order to continue the stimulation of the immune system (see Chapter 4).
Negative historical conditions slowed down medical and scientific world, so the next impor-
tant event in the field of allergy was the first DBPC trial of grass pollen subcutaneous immu-
notherapy published by Alfred Frankland in 1954 in Lancet [23], which proved beyond doubt
that subcutaneous immunotherapy was effective. The adequate number of patients (200), the
exact description of randomization (four randomization groups), blinding, and of dropouts
makes this study even today being rated as of moderately high scientific quality [15]. In 1957
Douglas Johnstone published early results and in 1968 late results of the study which was
realized on the same group of paediatric patients. The research was focused on a preventive
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and dose–response effect of immunotherapy in terms of bronchial hypersensitivity and
development of asthma [24, 25].
At the 1987 meeting of the EAACI on Mallorca, 40 specialists formed a subcommittee on
immunotherapy and decided to create some guidelines for indications of allergen immuno-
therapy, monitoring of effect and side effect, practical information, and requirements for
allergen extracts. The new common guidelines would serve for all specialists not only in the
European countries, but also on a worldwide basis. So the first position paper was published
in 1988 as Supplement of Journal Allergy [26]. New insights into the pathogenesis of allergic
diseases and new publications on immunotherapy have called for its revision. Immunotherapy
position paper was introduced to public in 1993 [27].
In 1996 in the United States, AAAAI together with ACAAI published practice parameters for
allergen immunotherapy [28]. After the great discussion at the level of World Health Organi-
zation (WHO) and various allergy, asthma, and immunology societies throughout the world
specialists took the decision to prepare common guidelines and in 1998 WHO position paper
“Allergen immunotherapy: therapeutic vaccines for allergic diseases” was published [29].
Practice parameters for allergen immunotherapy in the United States were updated in 2007
and 2011 under the principal editor Linda Cox. In the preparation of these updates, the
comprehensive search of the literature, information from articles known to the authors were
considered. Published clinical studies were rated by category of evidence and used to establish
the strength of a clinical recommendation. Published updates represent an evidence-based,
broadly accepted consensus opinion [30, 31]. All these clinical guidelines are designed to assist
clinicians by providing a framework for the evaluation and treatment of patients and are not
intended to replace a clinician’s judgment or establish a protocol for all patients [31].
3. Mechanisms of subcutaneous allergen immunotherapy
WHO position paper defines allergen immunotherapy as the administration of gradually
increasing quantities of an allergen vaccine to an allergic subject, reaching a dose which is
effective in ameliorating the symptoms associated with subsequent exposure to the causative
allergen [29]. The ultimate goal of the therapy is to induce immune tolerance, a change in the
immune response to specific antigens so that discontinuation of the therapy results in sustained
long-lasting therapeutic benefits.
Allergen immunotherapy modifies the response to allergen exposure by inducing tolerance,
but the mechanisms by which immunotherapy mediates its anti-inflammatory effects remain
incompletely defined because of the use of heterogeneous medicaments, treatment protocols,
routes of administration, and outcome measures in different studies. However, several
common features emerge from the multiple studies show that allergen immunotherapy
modifies the responses of antigen-presenting cells, T-cells and B-cells, as well as both the
number and the function of effector cells. So allergen immunotherapy regulate regulate the
local and systemic allergic inflammation [32].
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Successful immunotherapy in respiratory allergy is associated with the immunodeviation of
Th2 response to a more protective allergen-specific Th1 cells and with the induction of IL-10-/
TGF-β-producing T regulatory cells in blood and also locally in inflamed airways. In subcu-
taneous route of administration (SCIT), allergen-specific T-cell proliferation has been reduced
because of peripheral tolerance mechanisms. Immunoregulatory activity of T regulatory cells
has been claimed to be the main mechanism for clinical efficacy of SCIT [33]. Production of
IL-10 and TGF-b from an expression of cytotoxic T-lymphocyte-associated protein-4 by T
regulatory cells have importance in immune regulation in SCIT.
3.1. Immunological processes
Four groups of immunological processes can be classified during the course of allergen
immunotherapy [34]:
3.1.1. Group 1
An initial event is desensitization of FcεRI-bearing mast cells and basophils by allergen. The
mechanism of this desensitization is not fully elucidated, although its major role is assigned
to a rapid upregulation of the histamine 2 receptor, which is a major suppressor of basophil
activation. At the beginning of treatment, decreases in mast cell and basophil activity, degra-
nulation and tendency for systemic anaphylaxis degranulation take place within the first
hours. Histamine 2 receptor strongly suppressed FcεRI-induced activation and mediator
release of basophils, including histamine and leukotriene sulphides, as well as cytokine
production in vitro [35].
3.1.2. Group 2
Second group represents generation of allergen-specific T and B regulatory cells and suppres-
sion of allergen-specific Th1 and Th2 cells. T regulatory cells are a diverse group of T cells that
are active in the regulation of immune responses, and allergen-specific T regulatory cells
(CD4+CD25+) have been demonstrated after allergen immunotherapy [36]. T regulatory cells
have distinct cytokine profiles other than Th1 and Th2 cells, are characterized by IL-10 and
TGF-β secretion capacity, and express suppressor molecules, such as cytotoxic T-lymphocyte-
associated protein 4 (CTLA-4) and programmed cell death protein 1 (PD-1) [37].
IL-10 is the leading cytokine, which in T regulatory cell/B cell interaction suppresses specific
IgE production. In addition, IL-10 induces specific IgG4 production. IgG4 and probably IgG1
compete with IgE on the surface of mast cells and basophils for allergen binding [37]. They
produce interleukin IL-10 and transforming growth factor TGF-β, and have the potential to
suppress local Th2 cell responses and redirect antibody class switching in favour of IgG4 (IL10
isotype switch factor), and IgA (TGF-β isotype switch factor) [5].
Allergen-specific IgG4 antibodies interrupt allergen presentation to Th2 cells and, in addition,
block allergen-induced activation of mast cells and basophils, thereby significantly weakening
the allergic reaction [5]. Although multiple factors contribute, it could be supposed that the
tolerant state of specific cells essentially results from increased IL-10 secretion [38]. IL-10
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particularly originates from activated and antigen-specific T regulatory and B regulatory cell
populations and increases during allergen immunotherapy as well as in natural allergen
exposure [39].
3.1.3. Group 3
These processes include regulation of antibody isotypes demonstrating an early increase in
specific IgE levels, which later decrease, and an early and continuous increase in specific IgG4
levels. Natural exposure to a relevant allergen is often associated with an increase in IgE
synthesis. Similarly, allergen immunotherapy often induces a transient increase IgE levels in
serum, followed by a gradual decrease over months or years of continued treatment [40].
Allergen immunotherapy decreases allergen-specific IgE production and promotes allergen-
specific IgG4 production, which competes with IgE by blocking the binding of allergens to
FcεRI on the surface of mast cells and basophils [41]. IL-10 reduces allergen-specific IgE
production through IL-4-induced IgE switching and enhances allergen-specific IgG4 produc-
tion by inducing IL-4-induced gamma 4 transcript expression [42]. Grass pollen SCIT has
reduced seasonal increases in serum allergen-specific IgE, whereas 60- to 80-fold increases in
allergen-specific IgG and 100-fold increases in allergen-specific, IgG4 have been observed [43].
Thus, measuring IgG4 levels could be a good indicator of clinical efficacy of AIT during
follow-up [44].
Mechanisms of innate immunity are also stimulated during the course of allergen immuno-
therapy. Human blood dendritic cells from allergic subjects have impaired IFN-α production
following toll-like receptor-9 (TLR9) dependent innate immune stimulation. Tversky et al. [45]
found out subcutaneous allergen immunotherapy resulting in a fivefold increase in IFN-α
production and thus increases dendritic cell TLR9-mediated innate immune function, which
is impaired in allergic subjects.
3.1.4. Group 4
The fourth group of events takes place after several months from the beginning of the
treatment and these processes are characterized with decreases in tissue mast cells and
eosinophils and release of their mediators. The phase is referred as the late-phase response
and is localized in the peripheral tissues such as mucous membranes of respiratory organs
(nose, bronchi) or in the skin. When comparing immediate reactions mediated by mast cells,
last-phase response involves activation of T cells and the recruitment, activation and persis-
tence of eosinophils at sites of allergen exposure. Chronic exposition to inhalant allergens
causes immunopathologic changes seen during the late-phase. Mucosal changes are associ-
ated with positivity of nasal and bronchial provocation tests and suggest the pathologic
conditions of chronic allergic inflammation. Van Bever and Stevens [46] postulated that
allergen immunotherapy may resolve and/or reduce the severity of the late-phase reaction in
treated children. Rak et al. reported reduction in plasma levels of eosinophil cationic protein,
a marker of eosinophil activation, and chemotactic factors for eosinophils and neutrophils
correlate with decreased bronchial hyperreactivity and clinical improvement [47]. After grass
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pollen allergen immunotherapy decreased eosinophil and mast cell infiltration in nasal and
bronchial mucosa correlates with an anti-inflammatory effect [48, 49].
3.2. Involved cells
When describing above mentioned immunological processes, the expected role of many
immunological cells can be deduced (Figure 1). All these cells are involved in regulatory
processes and might contribute to the control of allergen-induced immune responses.
Figure 1. Cells and processes during allergen immunotherapy. DC, dendritic cell; Treg, T regulatory cell; Th2, Th2 cell;
BC, B-cell; Eo, eosinophil; Ba, basophil; MC, mast cell; SCIT, subcutaneous allergen immunotherapy.
3.2.1. Antigen presenting cells (APCs)
APCs, particularly DCs, control both peripheral tolerance and immunity through the inter-
pretation of environmental signals that are associated with antigen encounter (such as
pathogen-associated molecular patterns). DCs in the airways control the pulmonary immune
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response and determine tolerance and immunity to newly encountered antigens. Several
studies support a role for DCs in the induction of T cells with a regulatory phenotype and
function, particularly IL-10-secreting T regulatory cells. These T regulatory cells are involved
in the inhibition of subsequent inflammatory response as well in protection against sensitiza-
tion to allergen and development of asthma in a mouse model, so T regulatory cells might be
important mediators of the beneficial action of allergen immunotherapy [32].
3.2.2. T cells
Allergen immunotherapy has been shown to modify T-cell responses to allergen in several
ways. The main role is in switching Th1/Th2 ratio by increasing the allergen-induced Th1
cytokines to Th2 cytokines [50]. In other way, allergen immunotherapy can induce epitope-
specific T-cell anergy, generate allergen-specific T regulatory cells that can suppress the
responses of effector T cells following delivery of either whole allergen extracts or synthetic
peptides that contain or consist of a T-cell epitope and increase the production of cytokines
with regulatory activity [51]. Regulatory T cells also play an important role in controlling
allergic inflammation. The transcription factor Foxp3 regulates the development and function
of natural and adaptive CD4(+)CD25(+) T regulatory cells. Radulovic et al. detected the
presence of local Foxp3(+)CD25(+)CD3(+) cells in the nasal mucosa, their increased numbers
after immunotherapy, their association with clinical efficacy and suppression of seasonal
allergic inflammation. In conclusion, they supported a putative role for T regulatory cells in
the induction of allergen-specific tolerance in human subjects [52].
3.2.3. B cells
It is now generally accepted that peripheral tolerance is essential for a normal immune
response and successful immunotherapy of allergic disorders. As seen above, the tolerant state
essentially results from increased IL-10 secretion by T regulatory cells. Similar to Th cells, B
cells can be classified into subsets according to the cytokines they produce. One functional B-
cell subset, B regulatory cells, has recently been shown to contribute to the maintenance of the
fine equilibrium required for tolerance. B regulatory cells control excessive inflammatory
responses through IL-10, which inhibits proinflammatory cytokines and supports T regulatory
cell differentiation [53]. IL-10 not only generates tolerance in T cells, but it also regulates specific
isotype formation and skews B cells specific response from an IgE to an IgG4-dominated
phenotype. In addition to IgE/IgG4 switching, recent studies have also provided evidence for
increases in the amount of TGF-β driven allergen-specific IgA following allergen immuno-
therapy, indicating that other B cell production (antibody classes) might contribute to clinical
efficacy [54].
3.2.4. Effector cells (mast cells, basophils, eosinophils) and indirect influences
Late-phase reaction involves the recruitment, activation, and persistence of eosinophils, mast
cells, and activation of T cells at sites of allergen exposure. It is usually associated with
increased bronchial and nasal hyper responsiveness and suggests the pathologic conditions
present in chronic allergic inflammation. It has been postulated that the effect of allergen
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immunotherapy on the late-phase reaction is relevant to its clinical efficacy [46]. After a few
months, a decrease in tissue mast cell and eosinophil numbers and release of their mediators
is observed, as well as a decrease in the late-phase response. These effects are partially
demonstrated in SLIT and are rather weak compared with those seen in SCIT [55].
In addition, allergen immunotherapy exhibits indirect inhibition of Th2 cell-associated
phenomena (such as mucus production, and endothelial cell activation and cellular influx) and
Th1 cell-associated phenomena (such as epithelial cell activation and apoptosis).
In conclusion, when comparing clinical significance of SCIT and SLIT, due to well-established
safety profile, SLIT is considered an alternative to SCIT [55]. However, immunologic mecha-
nisms of SLIT are less well-elucidated than those for SCIT. All potential mechanisms seem to
be similar in both forms of allergen immunotherapy—in induction of T-cell tolerance, gener-
ation of T regulatory cells, in the role of IL-10 and TGF-β as well as in the late-phase response
(decrease the presence of mast cells, eosinophils and release of their mediators). Furthermore,
subcutaneous administration in contrast to sublingual immunotherapy modifies the immune
response also in very early phase of desensitization, generates B regulatory cells and shows
clearly decrease in IgE and increase in blocking IgG4 [34].
4. Aluminium—basic adjuvant in subcutaneous allergen immunotherapy
Mineral adjuvant molecules such as calcium phosphate or aluminium hydroxide are broadly
used in human immunization as adjuvants in parenteral route of administration. While
aluminium salts are commonly included in vaccines against infectious pathogens with the aim
to elicit proinflammatory responses following activation of the inflammasome, in subcutane-
ous allergen immunotherapy, allergen extracts are adsorbed on aluminium hydroxide or
calcium phosphate as adjuvants in Europe, whereas in North America only soluble allergens
are used.
Like any vaccines, adjuvants to be associated with allergens are expected to allow simplifying
immunization regimens, and reaching efficacy faster and for a longer duration. Mechanisms
involved include both a depot effect (slow release of the allergen, formulation of the allergen
as particles to target antigen presenting cells) as well as interaction with the innate immune
system (activation of the inflammasome) [56].
Although allergy vaccines are usually well-tolerated, an additional expected benefit of
adjuvants in this field is to help lowering the allergen dose, thus improving the safety profile
with less local reactions to the site of administration. On the other side, none of commercially
available noninvasive sublingual products, which are considered as a safe and efficacious
alternative, contain any adjuvant. These vaccines are based on high-dose aqueous allergen
extracts presented either as drops or more recently as fast dissolving tablets or lyocs [57].
History shows that aluminum salts are being used as adjuvants in allergen immunotherapy
for many years. Aluminum is validated as safe adjuvant with few established side effects.
Biological potential of aluminum lays on its reactivity not only at injection site, but also
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elsewhere in the body. Aluminium hydroxide modifies the immune response to a range of
allergens and is generally used in multiple injections over extended time periods. Incidence of
adverse events increases more likely in the subsets of individuals predisposed to such
reactivity. Susceptibility to adverse events grows with the high body burden of aluminum, in
which allergen immunotherapy is the most probable source of the adjuvant molecule. But
neither the safety nor the toxicity of aluminum as adjuvant in subcutaneous allergen immu-
notherapy preparations have been confirmed [58].
Threshold values for foodstuffs established by authorities are regularly exceeded and alumi-
num compounds are routinely used as adjuvants in vaccinations. A big challenge for pharma
industry is to conduct clinical trials which confirm the benefit–risk relationship of long-term
use of aluminum as adjuvant in SCIT according to good pharmacovigilance practice. Long-life
time of accumulation of aluminum in every individual human body has undoubtedly the
potential to exert chronic toxic side effect, such as neurotoxicity. In the literature, one serious
disease, a neuromuscular disorder called macrophagic myofasciitis, is attributed to the persis-
tence of aluminium salts at injections sites in muscle [59].
However, there is still a lack of studies examining the possible relationship among the
development of such diseases, which may have a latency period of many years after the
application of SCIT. Predisposing an individual to an unnecessary high body burden of
aluminium should be avoided and could reasonably be considered [60]. Adverse events
associated with aluminium adjuvants in allergen immunotherapy could be also connected
with other more common conditions such as chronic fatigue syndrome or and autoimmune
diseases [61]. More common but less critical are local reactions, such as discolouration of skin,
urticaria, foreign body granulomas, subcutaneous sarcoidosis, progressive circumscribed
sclerosis, subcutaneous nodules, and pseudo-lymphoma. When indicating subcutaneous
route of administration, we have to consider aluminium as strong potent adjuvant in stimu-
lating or modifying immunity. However, on the other side, the toxicity, antigenicity, and in a
long-term possible body burden of aluminium have to be considered.
The other potent adjuvant used in subcutaneous allergen immunotherapy is calcium phos-
phate. Many studies have compared the effects and adverse effects of immunologic adjuvants,
and in most studies, it was reported that allergen immunotherapy that contained calcium
phosphate causes fewer reactions [62]. Nacaroglu et al. reported no association between
adjuvant content and the incidence of adverse effects. They also concluded that the frequencies
of local and wide local reactions during SCIT were lower than expected, and although systemic
reactions were frequently seen, no fatal reaction was observed in the published study. House
dust mite SCIT and multiple allergen use increased the risk of reaction [63].
5. Treatment protocols in subcutaneous allergen immunotherapy
Although allergen specific immunotherapy represents the only immune-modifying and
curative option available for patients with respiratory allergy, the optimal schedule for specific
subcutaneous immunotherapy is still unknown. All injections are given in the doctor’s surgery,
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because there is a small risk of inducing allergic reactions, which can become severe or even
life-threatening if not treated promptly and appropriately. Two major groups of parenteral
treatment courses are used in clinical praxis: intermittent (pre-seasonal) or continual (year-
long) course.
Intermittent treatment course is considered as pre-seasonal treatment with pollen allergens
(trees or grasses). The allergens are prepared by conversion into allergoids by treatment with
glutaraldehyde and are adsorbed onto L-tyrosine. The course should be completed before the
onset of the tree/grass pollen season. The three graduated doses constitute a complete dose for
1 year and can be followed by the pre-seasonal extension injections with three highest-dose
vials for continued clinical improvement. It is recommended that the treatment course should
be given in each of 3 successive years [64, 65].
Continuous all-year courses are used in the treatment of allergy to pollens, dust mites, moulds,
animal epithelia as well as in the treatment of insect venom allergy (bee/wasp). Duration of
such course lasts from 3 to 5 years and the course is divided into a build-up and a maintenance
phase. In the initial (build-up) phase, four administration schedules of immunotherapy have
been reported: conventional and three accelerated (cluster, rush, and ultra-rush) schedules
(Table 1). Conventional subcutaneous immunotherapy for allergy treatment needs one
injection per week. The duration of the conventional build-up phase varies but typically ranges
from 3 to 8 months to reach the maintenance dose. Maintenance treatment continues at constant
dosing and in the case of airway allergy, the duration of all treatment should be at least 3 years
[66, 67].
Conventional Cluster Rush Ultra-rush
Time consumption 1 injection/week 2–3 injection/
week 
2–3 full days 1 full day (+night)
Build-up phase  14–25 weeks 6 weeks 2–3 days 1 day
Arrangements  Check after 20 min Check after 30
min 
Premedication/2–3
consecutive day stay
Premedication/day stay (or
+ overnight)
Table 1. Administration schedules of subcutaneous allergen immunotherapy.
Accelerated immunotherapy build-up schedules allow the patient to achieve the benefits of
immunotherapy more rapidly, as the maintenance dose is reached sooner. Shorter up-dosing
schedules are desired, provide earlier clinical improvement and improved convenience,
though they introduce increased risk of adverse reactions. However, many cluster schedules
have similar adverse reaction rates to conventional schedules, and premedication significantly
decreases side effects. Additionally, there may be cost savings by reduced patient visits and
medication requirements [68]. To assess the safety of cluster SCIT, meta-analysis showed that
no differences existed in the incidence of either local adverse reaction or systemic adverse
reaction between the cluster group and control group. Based on the current limited evidence,
Immunotherapy - Myths, Reality, Ideas, Future74
this meta-analysis could not conclude affirmatively that cluster subcutaneous immunotherapy
was a safe and efficacious option for the treatment of patients with allergic rhinitis [69].
It is important to conclude that accelerated build-up schedules have advantages over conven-
tional schedules. They bring better compliance, cost effectiveness, and a reduction in dosage
errors since most patients can reach the maintenance dose in shorter time. The introduction of
premedication provides a safety profile similar to that of conventional schedules [70–72]. But
main decision in favouring the treatment course lies on the clinician who is the only responsible
person also in considering possible side effect of preferring the route of administration and
the chosen protocol.
At present, it is also unclear whether subcutaneous or sublingual allergen immunotherapy has
better outcomes. Subcutaneous protocols seem to be more effective in reducing symptoms for
dust mites and grass allergy, but no one could declare any conclusive evidence of superiority
of SLIT or SCIT because of a lack of true head-to-head studies. However, trend has favoured
SCIT as more effective therapy [73].
6. Future of subcutaneous allergen immunotherapy
Recent research of the cellular and molecular basis of allergic reactions has advanced contem-
porary understanding of the mechanisms involved in allergic diseases. Newly discovered
mechanisms have also helped the development of innovative approaches that are likely to
further improve the control of allergic responses in the future. Only allergen immunotherapy
induces immunological tolerance and changes the course of disease. Novel vaccines should
meet increasing needs for reduction in adverse effects, costs, and duration of treatment [74].
The vaccines have to induce long-term tolerance to allergens.
The efficacy of allergen immunotherapy for the treatment of respiratory allergy (allergic
rhinoconjunctivitis with or without bronchial asthma) has been clearly demonstrated in
numerous well-designed, placebo-controlled trials. One of the most important studies was the
PAT study. PAT study was conducted on children with allergic rhinoconjunctivitis and
followed for 10 years with asthma development as the primary outcome. It showed that three
years of continuous subcutaneous allergen immunotherapy reduced the risk of developing
asthma in comparison to the control group. The difference was maintained at follow-up after
10 years [75].
All preparations that are currently available (standardized extract, allergoids, and recombinant
allergen) may trigger side effects. A higher risk is detected in subjects with accelerated dosing
schedules, and in subjects with asthma [76]. Contemporary research which is focusing on
different administration modalities includes epicutaneous and intralymphatic route of
administration of allergen extracts. Both novel strategies showed similar efficacy in the
treatment of grass pollen allergy. Results gathered from recent studies have shown less demand
on numbers of shots as well as on less total dose of allergen [77, 78].
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Other way for enhancing desirable immune response of allergens is the biological modification
of allergen preparations. Modification can be achieved using recombinant technology resulting
in modified proteins and peptides [74]. Such peptide-based allergen preparations which do
not bind IgE, induce increase in Il-10 and so consequently reduce the activity of mast cells as
well as the modulation of synthesis Th1 and Th2 cytokines [79].
Novel adjuvants, i.e. nucleotide immunostimulatory sequences derived from bacteria CpG or
monophosphoryl lipid A could be an alternative strategy in potentiating Th1 response of
subcutaneous allergen immunotherapy [79]. The addition of TLR agonists as adjuvants, their
use by themselves (TLR4, 8, 9), allergens coupled to virus-like particles or to hepatitis B PreS-
fusion peptide also have shown some benefits in the novel treatment strategies [73, 75].
Additive effect to the allergen immunotherapy in the treatment of allergic rhinitis and asthma
could be achieved by administration of anti-IgE recombinant humanized monoclonal anti-
body—omalizumab. Omalizumab which blocks the effects of IgE, improves efficacy, potenti-
ates immuno-modifying effect, and decreases adverse effects when administered along with
allergen immunotherapy. Although the cost of the combination of immunotherapy with anti-
IgE treatment is high, this should be considered in view of the enhanced benefit/risk ratio and
the known long-term benefits of allergen immunotherapy [79].
7. Author’s remarks
Subcutaneous allergen immunotherapy seems to be more effective, but still there is lack of true
head-to-head studies, favouring it as more effective therapy over sublingual treatment.
Accelerated build-up schedules have advantages over conventional schedules due to better
compliance, cost effectiveness, and a reduction in dosage errors since most patients can reach
the maintenance dose in shorter time. Even though final decision in favouring the treatment
course lies on the clinician who is the only responsible person also in considering possible side
effect of preferring the route of administration and the chosen protocol.
The author favours conventional schedules of subcutaneous route of therapeutic interventions.
Possibly, such view on the treatment process looks very conservative and from the perspective
of contemporary knowledge described above, could be “scientifically” unpopular. When
starting the treatment process in our office physician provides the patient with an example
that “Gaining lean body weight or training for muscle gain is a slow process that takes months
and years rather than days and weeks” and so the most efficient treatment with minimum risk
lies on application in subcutaneous form and under the conventional schedules.
Other argument using SCIT opposite to SLIT is the personal experience that almost no one
(mostly out of season) takes drops/tablets regularly, so the maximal dose-related effect could
not be expected. The idea of such non-compliance in common patient community in contrary
to patient community underwent the trial treatment with regular follows-up are indirectly
confirmed by information obtained from IMS reports (personal communication). Data from
IMS reports show the decrease in selling SLIT drugs in the period out of season.
Immunotherapy - Myths, Reality, Ideas, Future76
Given the lack of specific biomarker in monitoring treatment course, the main control
mechanism of efficacy is the evaluation of quality of life using simple evaluation scale as
visual analogue scale (VAS) or standardized respiratory allergy questionnaires. In evalua-
tion of quality of life-treated patients modified VAS-like questionnaire is used since 2015.
Multiple “umbrella” shaped visual analogue questionnaire is not one-parametric as visual
analogue scale, but it is not as complicated as many allergy-specific questionnaires either
[80].
Allergen upload for 1-year treatment is determined in 10–12 injected doses (one injection in
every 4–6 weeks recommended in SPCs). When patient forgets to keep advised dosing due to
personal non-compliance, he is kindly asked to hold the regular visits on the ground of
reaching highest efficacy after three to five year lasting treatment. It shows us good results of
indicated treatment as seen in evaluation of QoL questionnaires after finishing the treatment
course (unpublished data).
8. Conclusion
The presented review summarizes the literary-acquired knowledge as well as author’s own
experience in conducting aero-allergen immunotherapy, particularly in subcutaneous route of
administration for all modalities of respiratory allergy disease from allergic rhinosinusitis,
bronchial asthma to united airway disease. Because of appropriate efficacy in connection with
satisfactory safety the author favours conventional schedules of subcutaneous route of
therapeutic intervention.
The future of aero-allergen immunotherapy should be focused on new hypoallergenic
molecules/adjuvants, on new routes of allergen administration and on searching potential
biomarkers which could be objectively measured and easily accessible from body fluids (blood,
nasal secretion, sputum). The combination of estimated biomarkers obtained from biological
samples in conjunction with evaluation of quality of life could lead to the generation of the
overall satisfactory monitoring protocol. Due to enormous overload seen in the scientific
literature, it seems that ongoing research in the field of allergen immunotherapy will bring
even brighter future.
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